These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21282534)

  • 1. Was [¹⁸F]fluorodeoxyglucose positron emission tomography complete response after chemoradiotherapy defined as standardized uptake value(max-1 hour) ≤ 3 complete?
    Ma W; Wang J; Yang W; Li G; Wang S
    J Clin Oncol; 2011 Mar; 29(9):e248; author reply e249-50. PubMed ID: 21282534
    [No Abstract]   [Full Text] [Related]  

  • 2. (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer.
    Jingu K; Kaneta T; Nemoto K; Takeda K; Ogawa Y; Ariga H; Koto M; Sakayauchi T; Takai Y; Takahashi S; Yamada S
    Int J Clin Oncol; 2010 Apr; 15(2):184-90. PubMed ID: 20217449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
    Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
    Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. F-18-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer.
    Schmidt M; Bollschweiler E; Hölscher A
    Ann Surg; 2010 Aug; 252(2):412-3; author reply 413. PubMed ID: 20647915
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.
    Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Mori M; Endo K
    AJR Am J Roentgenol; 2010 Nov; 195(5):1204-11. PubMed ID: 20966329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Esophageal cancer: outcome according to therapeutic strategy].
    Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
    Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
    Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
    Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting response to chemoradiotherapy in rectal and oesophageal cancer with 18F-FDG: prognostic value and possible role in patient management.
    Hindié E; Hennequin C; Moretti JL
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1576-82. PubMed ID: 17579856
    [No Abstract]   [Full Text] [Related]  

  • 17. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluorodeoxyglucose positron emission tomography after definitive chemoradiotherapy in patients with oesophageal carcinoma.
    Di Fiore F; Blondin V; Hitzel A; Edet-Sanson A; Benyoucef A; Huet E; Vera P; Michel P
    Dig Liver Dis; 2012 Oct; 44(10):875-9. PubMed ID: 22883219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.
    Westerterp M; Omloo JM; Sloof GW; Hulshof MC; Hoekstra OS; Crezee H; Boellaard R; Vervenne WL; ten Kate FJ; van Lanschot JJ
    Int J Hyperthermia; 2006 Mar; 22(2):149-60. PubMed ID: 16754598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.